
Cancers known as neuroendocrine tumours start in specialised cells known as neuroendocrine cells. Neuroendocrine cells have characteristics of both hormone-producing and nerve cells.
Although they are uncommon, neuroendocrine tumours can develop anywhere in the body. Most neuroendocrine tumours develop in the pancreas, rectum, small intestine, appendix, and lungs.
Neuroendocrine tumours come in a variety of forms. Some grow very swiftly, while others grow slowly. Excess hormones are produced by certain neuroendocrine tumours (functional neuroendocrine tumours). Nonfunctional neuroendocrine tumours either don't release hormones at all or don't release enough to produce symptoms.
NETs are characterised according to their origin and whether they are operational (producing hormones) or non-functioning. They can arise in different organs. The following are a few typical NET types:
The term "gastrointestinal neuroendocrine tumours" (GI NETs) refers to tumours that develop in the stomach, small intestine, colon, and rectum.
Pancreatic neuroendocrine tumours (PNETs) can be either non-functional or functioning, producing hormones such as glucagon or insulin.
Thyroid neuroendocrine tumours are rare growths in the thyroid gland, including medullary thyroid cancer, which begins in the thyroid's calcitonin-producing C-cells.
Adrenal neuroendocrine tumours occur in the adrenal glands, which sit above the kidneys and generate the chemicals cortisol and adrenaline.
CarcinoidTumour: One of the subtypes of neuroendocrine tumours, carcinoid tumours are most commonly found in the gastrointestinal system, particularly in the small intestine, appendix, and rectum. Some cancers produce or do not produce hormones.
Early treatment of neuroendocrine tumours (NETs) is essential for enhancing patient outcomes. Early intervention and detection can prevent the tumour from spreading or becoming more malignant. NETs may develop slowly, and symptoms do not usually appear until the tumour has progressed, so early diagnosis is vital. Early treatment of NETs gives the best hope of successful surgery, possibly removing the tumour before it metastasises.
Moreover, early intervention can control hormone-related symptoms and avoid complications such as hormone overproduction, enhancing the patient's quality of life. Because NETs exhibit a wide range of behaviours, early treatment also ensures a more specific treatment modality, enhancing overall prognosis.
Initial signs and symptoms are not usually present in neuroendocrine tumours. Your tumour's location and whether it produces too many hormones will determine the symptoms you might experience.
Signs and symptoms of neuroendocrine tumours generally may include:
Excessive hormone production by neuroendocrine tumours (functional tumours) may result in:
Causes
Risk Factors
In Malaysia, Peptide Receptor Radionuclide Therapy (PRRT) has been found to be an encouraging treatment for metastatic neuroendocrine tumours (NETS). In a retrospective analysis of 73 treated patients, there was evidence of a 47% objective response rate and an 83% disease control rate. The treatment was tolerated well, with few severe adverse effects; interestingly, there was no renal toxicity even among patients with chronic kidney disease.
Surgery: The tumour is surgically removed. Surgeons attempt to take out as much of the surrounding healthy tissue as possible, along with the entire tumour. Remove as much of the tumour as possible if complete removal is impossible.
Chemotherapy: Chemotherapy uses powerful drugs to destroy tumour cells. It may be taken orally or injected into an arm vein. If your neuroendocrine tumour recurs after surgery, chemotherapy is recommended. It can also help cancers that are too advanced to remove with surgery.
Cost Start From USD 1500 - USD 3500Explore Options
Targeted Therapy: Targeted medication therapies concentrate on particular abnormalities in tumour cells. Targeted pharmacological treatments can potentially kill tumour cells by preventing these aberrations. Chemotherapy and targeted medication therapy are typically used in conjunction with advanced neuroendocrine tumours.
Cost Start From USD 2000 - USD 10000Explore Options
Radiation Therapy: This treatment employs intense energy beams, such as protons and X-rays, to destroy tumour cells. It may be effective for certain neuroendocrine tumour types. It could be suggested in cases where surgery is not a possibility.
MediRehab (chain of Rehab centres - Part of MediGence) provides comprehensive rehabilitation services to support patients through Teleconsultations and online therapy sessions.









Kuala Lumpur, Malaysia
Sunway Medical Centre has initiated a comprehensive expansion plan close to its current hospital facility to enhance its ability to provide services to the global market. The new Cancer Radiosurgery Center and Nuclear Medicine Center, which will also house additional Centers of Excellence like the Digestive Health Center and Dialysis Center, marked the completion of Tower C's first phase in October 2016.

Kuala Lumpur, Malaysia
Prince Court is a private medical facility in the center of Kuala Lumpur that has 277 individual beds. Our dedication is to provide you with the best treatment possible from the time you arrive until you depart, healthier and happier. We are well-known for our top-notch facilities, cutting-edge technology, and friendly customer service.

Kuala Lumpur, Malaysia
Subang Jaya Medical Center is renowned for pioneering radiation oncology treatments and infrastructure in Malaysia. The hospital also has a state-of-the-art Cancer Radiosurgery Centre (CRC), which is fully furnished with the latest medical technology for cancer detection, monitoring, and treatment.
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Malaysia is suitable for treating neuroendocrine tumours (NETs) due to its skilled oncologists, advanced medical technology, and affordable healthcare. The country offers various therapeutic options, including peptide receptor radionuclide therapy (PRRT), targeted drugs, chemotherapy, and surgery. Many hospitals in Malaysia are equipped with multidisciplinary treatment and international accreditation.
Neuroendocrine tumours (NETs) can be benign or malignant, depending on their rate of growth and metastasis. Because benign NETs grow very slowly, they are noncancerous and never metastasise to other body regions. They often only require surgical removal. However, malignant NETs grow more aggressively, are carcinogenic, and potentially metastasise to other organs, requiring more aggressive treatments, including surgery, chemotherapy, or other therapies.
Yes, neuroendocrine tumours (NETs), particularly malignant ones, can migrate to other areas of the body. This process is called metastasis. The liver, lungs, bones, and lymph nodes are familiar places for spreading NETs. The tumour's size, grade, and whether it is malignant or benign all affect its tendency to spread.
Somatostatin therapy uses synthetic forms of somatostatin, a hormone that usually regulates the secretion of several other hormones, to treat neuroendocrine tumours (NETs). Somatostatin analogues suppress the tumours' secretion of excessive hormones, reducing symptoms like flushing, diarrhoea, and other side effects. By binding to specific receptors on NET cells, these treatments also reduce tumour activity and, in some cases, reduce the size of the tumours, slowing their development.
The prognosis of a neuroendocrine tumour (NET) depends on tumour grade (its rate of growth), stage (whether it has spread), site, and hormone production. The prognosis is typically worse for high-grade tumours and those that have spread. Factors related to the patient, including overall health, age, and response to treatment, also impact the prognosis.
Surgical removal of tumours, if possible, chemotherapy or targeted therapy for more severe cases, and medications such as somatostatin analogues to treat hormone-related symptoms are all involved with treating the symptoms of a neuroendocrine tumour (NET). To improve overall comfort, symptoms might also be treated with painkillers, antidiarrheals, and changes in diet. Symptom treatment and quality of life can be enhanced with an individualised treatment plan developed with input from a medical team.
Yes, you can get a second opinion on Neuroendocrine tumour treatment in Malaysia through MediGence. With MediGence, you can connect with highly experienced professionals from top Malaysian hospitals who can provide additional information regarding your diagnosis and treatment options. The platform facilitates easy access to professional help so you can make informed healthcare choices and receive the best care possible.
For localised NETS, surgery is a typical therapy to stop the tumour from growing further. The feasibility of surgery depends on the tumour's size, location, and involvement of other organs.
To find a certified cancer specialist, search MediGence’s website, which offers a list of top-class and internationally trained oncologists from the best hospitals in Malaysia. Through MediGence, you can search the profiles of specialists, check their credentials, reviews, and experience, and book online consultations. To get the best care for your condition, the website also assists you in finding the best hospitals and provides personalised assistance for your health requirements.